Ancora Heartincis A Medical Device Company Based In Santa Claracaliforniadedicated To Developing Innovative Therapies For Heart Failurefounded In 2001Ancora Specializes In Minimally Invasivetranscatheter Treatments That Address Structural Heart Issuesparticularly For Patients With Reduced Ejection Fractionhfref The Company Was Acquired By Scilex Holding Company In July 2022 And Has Raised Approximately $151 94 Million In Funding To Support Its Clinical Initiatives One Of Ancora S Key Products Is The Accucinchaventricular Restoration Systemdesigned To Restore The Structure And Function Of The Enlarged Left Ventricle In Hfref Patientsthis Device Is The First Of Its Kind To Target Ventricular Remodelinga Significant Factor In Heart Failure Progressionancora Is Currently Conducting The Corcinch Hf Pivotal Trial To Evaluate The Safety And Efficacy Of The Accucinch Systemaiming For Fda Approvalthe Company Also Collaborates With Egniteincto Enhance Patient Enrollment In Clinical Trials Through Ai Driven Tools
